Skip to main content
Premium Trial:

Request an Annual Quote

Dako, Amgen to Collaborate on Personalized Cancer Dx

NEW YORK (GenomeWeb News) – Dako said today that it will collaborate with Amgen to develop a diagnostic test for a drug candidate for treating a rare and deadly form of cancer.

The company did not specify the type of cancer Amgen will target in this collaboration.

"Our agreement with Amgen is one of several partnerships that Dako has entered with pharma companies to enable the development of diagnostic tests to predict which patients are most likely to respond to specific treatments," Dako CEO Lars Holmkvist said in a statement.

The company has struck similar agreements over the past two years with AstraZeneca, Bristol-Myers Squibb, and Genentech.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.